scholarly journals Acute Exacerbations of Idiopathic Pulmonary Fibrosis

Respiration ◽  
2013 ◽  
Vol 86 (4) ◽  
pp. 265-274 ◽  
Author(s):  
Katerina M. Antoniou ◽  
Athol U. Wells
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Acute Exacerbations

scholarly journals Initial therapeutic dose of corticosteroid for an acute exacerbation of IPF is associated with subsequent early recurrence of another exacerbation

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Ryo Yamazaki ◽  
Osamu Nishiyama ◽  
Sho Saeki ◽  
Hiroyuki Sano ◽  
Takashi Iwanaga ◽  
...  
Keyword(s):  
Risk Factors ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Therapeutic Dose ◽  
Early Recurrence ◽  
Time To Recurrence ◽  
Acute Exacerbations ◽  
Patient Groups ◽  
The Mean ◽  
Mean Time

AbstractSome patients with idiopathic pulmonary fibrosis (IPF) undergo recurrent acute exacerbations (AEs). This study aimed to elucidate the risk factors for recurrent AEs of IPF (AE-IPF). Consecutive patients with IPF admitted for their first AE-IPF between January 2008 and December 2018 were retrospectively recruited. Of 63 patients admitted for an AE-IPF and discharged alive, 9 (14.3%) developed a recurrence of AE within 1 year. The mean time to recurrence was 233 ± 103 days. Total doses (mg/month and mg/kg/month) of corticosteroids administered over day 1 to 30 after the AE were significantly higher in patients without recurrences of AE-IPF (5185 ± 2414 mg/month, 93.5 ± 44.0 mg/kg/month) than the doses in patients with recurrences (3133 ± 1990 mg/month, 57.2 ± 37.7 mg/kg/month) (p = 0.02 and p = 0.03, respectively). However, no differences were observed between the total doses of corticosteroids administered over days 31 to 60, 61 to 90, 91 to 120, and 151 to 180 after the AE. Furthermore, differences between the administration rates of immunosuppressive and antifibrotic treatments administered to the 2 patient groups were not significant. An increased total dose of corticosteroid administered over day 1 to 30 after an AE-IPF was associated with a decreased risk of subsequent recurrence of AE-IPF within 1 year after the first AE.

scholarly journals Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids

Breathe ◽  
2020 ◽  
Vol 16 (3) ◽  
pp. 200086
Author(s):  
Christopher J. Brereton ◽  
Helen E. Jo
Keyword(s):  
Disease Management ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Supportive Care ◽  
Disease Process ◽  
Evidence Base ◽  
Fatal Complication ◽  
Acute Exacerbations ◽  
International Awareness

An acute exacerbation of idiopathic pulmonary fibrosis (AEIPF) is a potentially fatal complication of an already debilitating disease. Management is currently centred on delivering excellent supportive care and identifying reversible triggers. Despite growing international awareness and collaboration, no effective therapies have been identified. Corticosteroids are often the mainstay of treatment; however, the evidence base for their use is poor. Here, we review our current understanding of the disease process and how to manage it, with a focus on the role of corticosteroid therapy.

An Algorithm to Tackle Acute Exacerbations in Idiopathic Pulmonary Fibrosis

2008 ◽  
Vol 177 (12) ◽  
pp. 1397-1397 ◽  
Author(s):  
Wim A. Wuyts ◽  
Michiel Thomeer ◽  
Lieven J. Dupont ◽  
Geert M. Verleden
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Acute Exacerbations

scholarly journals Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations

2015 ◽  
Vol 9s1 ◽  
pp. CCRPM.S39897 ◽  
Author(s):  
Yutaro Nakamura ◽  
Takafumi Suda
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Interstitial Fibrosis ◽  
Clinical Manifestations ◽  
Current Status ◽  
Acute Exacerbations ◽  
New Treatments ◽  
Disease Profiling ◽  
Parenchymal Lung Disease ◽  
Made In

Idiopathic pulmonary fibrosis (IPF) is a parenchymal lung disease characterized by progressive interstitial fibrosis. The clinical course of IPF can be unpredictable and may be punctuated by acute exacerbations. Although much progress is being made in unraveling the mechanisms underlying IPF, effective therapy for improving survival remains elusive. Longitudinal disease profiling, especially in terms of clinical manifestations in a large cohort of patients, should lead to proper management of the patients and development of new treatments for IPF. Appropriate multidisciplinary assessment in ongoing registries is required to achieve this. This review summarizes the current status of the diagnosis and clinical manifestations of IPF.

Visual and fully-automated CT analysis in acute exacerbations of idiopathic pulmonary fibrosis (IPF)

2018 ◽  
Author(s):  
Lars Kehler ◽  
Tobias Norajitra ◽  
Julia Ley-Zaporozhan ◽  
Athanasios Giannakis ◽  
Roman Rubtsov ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Acute Exacerbations ◽  
Ct Analysis

Differences of acute exacerbations in idiopathic pulmonary fibrosis compared to other fibrotic lung diseases

2019 ◽  
Author(s):  
Paola Faverio ◽  
Stefania Cerri ◽  
Maria Rosaria Pellegrino ◽  
Giulia Dei ◽  
Enrico Clini ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Lung Diseases ◽  
Acute Exacerbations ◽  
Fibrotic Lung Diseases

scholarly journals Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis

2011 ◽  
Vol 40 (1) ◽  
pp. 93-100 ◽  
Author(s):  
Eoin P. Judge ◽  
Aurelie Fabre ◽  
Huzaifa I. Adamali ◽  
Jim J. Egan
Keyword(s):  
Pulmonary Hypertension ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Acute Exacerbations

scholarly journals Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis

2017 ◽  
Vol 18 (1) ◽  
Author(s):  
Philip L. Molyneaux ◽  
Michael J Cox ◽  
Athol U. Wells ◽  
Ho Cheol Kim ◽  
Wonjun Ji ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Acute Exacerbations ◽  
Respiratory Microbiome
Sign in / Sign up

Export Citation Format

Share Document